Sugammadex
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anesthesia, General
Conditions
Anesthesia, General
Trial Timeline
Oct 4, 2005 → Sep 15, 2006
NCT ID
NCT00552929About Sugammadex
Sugammadex is a phase 2 stage product being developed by Merck for Anesthesia, General. The current trial status is completed. This product is registered under clinical trial identifier NCT00552929. Target conditions include Anesthesia, General.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05276804 | Phase 3 | Completed |
| NCT03196167 | Approved | Completed |
| NCT02011490 | Phase 1 | Completed |
| NCT00826176 | Phase 3 | Completed |
| NCT00702715 | Phase 3 | Completed |
| NCT00535496 | Phase 3 | Completed |
| NCT00591786 | Phase 2 | Completed |
| NCT00552929 | Phase 2 | Completed |
| NCT00482599 | Phase 3 | Completed |
Competing Products
20 competing products in Anesthesia, General